GlassScriptPhysician profile
Mary E Moccia
NPI 1144778655
$3,368.51
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,029 · 2022: $1,339.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.67 | 2021-2022 | |
| Ucb, INC. | $430.47 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $376.64 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $354.18 | 2021-2022 | |
| Leo Pharma INC. | $321.44 | 2021-2022 | |
| Genzyme Corporation | $276.60 | 2021-2022 | |
| Lilly USA, LLC | $229.43 | 2021-2022 | |
| Incyte Corporation | $126.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $120.64 | 2021 | |
| Pfizer INC. | $119.82 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $86.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.73 | 2021 | |
| Galderma Laboratories, L.P. | $63.93 | 2021-2022 | |
| Amgen INC. | $46.87 | 2021 | |
| Janssen Biotech, INC. | $34.02 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $27.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Moccia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.